Bridging the Gap from "Paper" to "Patient": An Overview and Quality Assessment of PET/CT-Based Radiomics for Prostate Cancer Using the Updated RQS 2.0.

In 30 seconds

This systematic review evaluated the methodological quality and clinical translation maturity of PET-based radiomics studies in prostate cancer using the updated Radiomics Quality Score (RQS 2.0). A total of 39 studies were assessed, revealing a mean total RQS score of 14.59 ±3.90, equating to an RQS% of 40.4% ± 11.0%.

Key findings

• The mean total RQS score was 14.59 ±3.90, with an RQS% of 40.4% ± 11.0%.
• Inter-rater agreement for total RQS was excellent (ICC = 0.89).
• No studies reached RRL level 8 or higher, indicating limited clinical translation maturity.
• Key deficiencies were noted in automated segmentation and multicenter validation.

Why it matters

Understanding the quality and readiness of PET-based radiomics studies is crucial for clinicians as it informs the potential integration of these technologies into clinical practice for prostate cancer management.